Novimmune
Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases.[1] The company was founded in 1998.[2]
Novimmune has six publicly disclosed drug in their pipeline:
- CD3ε antibody being developed in partnership with Tiziana Life Sciences. Phase II trials in patients with Crohn's disease and transplant rejection finished in 2008 and 2009, respectively.[5]
- breakthrough status to the drug in 2016.[9]
- NI-1401, an anti-IL17 drug being developed in partnership with Genentech for inflammatory and auto-immune diseases.[10]
- B-cellhematological cancers.
- bispecific antibody in the preclinical phase of development for treatment of solid tumors.[11]
No drugs have been approved yet.
References
- ^ "Novimmune's NI-0501 Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With Primary Hemophagocytic Lymphohistiocytosis (HLH) - FierceBiotech". www.fiercebiotech.com.
- ^ "Novimmune SA: Private Company Information - Bloomberg". www.bloomberg.com.
- ^ "First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers - Full Text View - ClinicalTrials.gov".
- ^ "Pipeline - NI-0101 anti-TLR4". www.novimmune.com.
- ^ "NI-0401 in Patients With Acute Renal Allograft Rejection - Full Text View - ClinicalTrials.gov".
- ^ "Pipeline | NI-0501 anti-IFNγ". Archived from the original on 2017-01-13. Retrieved 2017-01-11.
- ^ "Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody - Full Text View - ClinicalTrials.gov".
- ^ "A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis - Full Text View - ClinicalTrials.gov".
- ^ "Emapalumab - NovImmune - AdisInsight". adisinsight.springer.com.
- ^ "Pipeline - NI-1401 anti-IL17". www.novimmune.com.
- ^ "Pipeline - NI-1801 anti-CD47/Mesothelin". www.novimmune.com.